128009-22-3

Basic information

• Product Name: methyl 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylate
• Synonyms: methyl 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylate
• CAS NO: 128009-22-3
• Molecular Weight: 444.482
• Mol File: 128009-22-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylate(128009-22-3)
• EPA Substance Registry System: methyl 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylate(128009-22-3)

Safety Data

• Hazardous Substances Data: 128009-22-3(Hazardous Substances Data)

Upstream product

• 30461-77-9 methyl 3,4-dimethoxycinnamate 
• 244612-91-7 tetrakis(Boc-caracasandiamide) 
• 201858-52-8 ethyl 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylate 
• 201858-53-9 3β,4β-bis(3',4'-dimethoxyphenyl)-1α,2α-cyclobutanedicarboxylic acid 
• 20583-78-2 ethyl (E)-3,4-dimethoxycinnamate 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 

Relevant articles and documents

Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide

Caracasandiamide, a second hypotensive agent isolated from Verbesina caracasana, is the cyclobutane dimer (truxinic type) of the previously reported 1-[(3,4-dimethoxycinnamoyl)amino]4-[(3-methyl-2- butenyl)guanidino]butane (caracasanamide) (Delle Monache, G.; et al. BioMed. Chem. Lett. 1992, 25, 415-418). The structure was confirmed by synthesis starting from β-truxinic acid obtained by photoaddition of 3,4- dimethoxycinnamic acid. The dimer was coupled with 2 mol of prenylagmatine to give caracasandiamide in satisfactory yield. By contrast, the direct photodimerization of caracasanamide was unsuccessful. Caracasandiamide, assayed by the iv route in anesthetized rats at doses ranging from 50 to 3200 μg/kg of body weight, was found to have no appreciable effect on heart rate. At lower doses, the drug stimulates breathing and increases cardiac inotropism, stroke volume, and cardiac output, thus augmenting blood pressure and aortic flow. At higher doses, caracasandiamide depresses breathing likely through central neurogenic mechanisms (not involved in the cardiovascular effects), continues to stimulate cardiac inotropism, and induces, by reducing peripheral vascular resistance, arterial hypotension with reduction of both aortic flow and stroke volume. These cardiovascular effects appear to involve complex interactions at the level of the peripheral β1-, β2-, and α2- adrenoreceptor-dependent as well as M2- and M4-cholinergic receptor- dependent transductional pathways both in cardiovascular myocells and at the level of the postganglionic sympathetic endings (with reserpine- and guanethidine-like mechanisms). The cardiovascular effects of caracasandiamide, different from those of caracasanamide, do not depend on significant actions on the central nervous system and on baroreflex pathways. In a similar manner and more effective than caracasanamide, caracasandiamide may be considered a hypotensive and antihypertensive drug. It is devoid of some of the negative side effects, e.g., reflex tachycardia and decreased cardiac inotropism, which are shown by the majority of the most common antihypertensive and vasodilator drugs.

Photochemical dimerization of methoxy substituted cinnamic acid methyl esters

Photochemical dimerization of methyl methoxycinnamates was studied. Dimer formation was observed both in unsensitized and in sensitized reactions. The reactions showed a high stereoselectivity.